id: NEW:cannabis_use_during_oud_treatment_to_prescription_opioid_misuse
name: Cannabis Use During OUD Treatment â†’ Non-Medical Opioid Use
from_node:
  node_id: NEW:cannabis_use_during_oud_treatment
  node_name: Cannabis Use During OUD Treatment
to_node:
  node_id: prescription_opioid_misuse
  node_name: Non-Medical Opioid Use
direction: positive
category: behavioral
mechanism_pathway:
- 'Step 1: Individuals receiving pharmacotherapies (methadone, buprenorphine, naltrexone) for opioid use
  disorder may concurrently use cannabis'
- 'Step 2: Cannabis use could theoretically interact with opioid treatment through shared neurobiological
  pathways involving endocannabinoid and opioid receptor systems'
- 'Step 3: Meta-analysis of longitudinal studies finds no statistically significant association between
  cannabis use and return to non-medical opioid use during treatment'
- 'Step 4: Pooled analysis suggests cannabis use neither increases nor decreases risk of non-medical opioid
  use among those in MOUD treatment'
evidence:
  quality_rating: A
  n_studies: 10
  primary_citation: 'Gabriel P A Costa et al. 2024. "The impact of cannabis on non-medical opioid use
    among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis
    of longitudinal studies." https://doi.org/10.1080/00952990.2023.2287406'
  supporting_citations:
  - Additional citations require full-text access - meta-analysis included 10 longitudinal studies
  - Studies utilized methadone (76.3%), buprenorphine (21.3%), and naltrexone (2.4%) treatment modalities
  - Average follow-up across studies was 9.7 months (SD = 3.77)
  doi: 10.1080/00952990.2023.2287406
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: 'This systematic review and meta-analysis of 10 longitudinal studies (N=8,367) found no significant
  association between cannabis use and non-medical opioid use among patients receiving medications for
  opioid use disorder. The pooled odds ratio was 1.00 (95% CI: 0.97-1.04, p=0.98), indicating cannabis
  use neither increased nor decreased the risk of returning to non-medical opioid use during MOUD treatment.'
quantitative_effects:
  effect_size:
    value: 1.0
    type: odds_ratio
    ci_lower: 0.97
    ci_upper: 1.04
  p_value: 0.98
  sample_size: 8367
moderators:
- name: OUD treatment modality
  direction: strengthens
  strength: moderate
  description: Sensitivity analysis conducted to understand potential differences between methadone, buprenorphine,
    and naltrexone treatment modalities
- name: Follow-up duration
  direction: strengthens
  strength: weak
  description: Follow-up time ranged from 4 to 15 months (mean 9.7 months), which may affect detection
    of associations
structural_competency:
  equity_implications: This finding has important policy implications for substance use treatment programs.
    Many MOUD programs require cannabis abstinence as a condition of treatment enrollment or continuation.
    The null finding challenges this structural barrier to treatment access, suggesting that cannabis
    abstinence requirements may unnecessarily restrict access to life-saving opioid treatment without
    evidence of benefit. This has equity implications as cannabis policies and enforcement disproportionately
    affect marginalized communities, creating additional barriers to OUD treatment for already underserved
    populations.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.445958'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
